2025-04-22 - Analysis Report
## UnitedHealth Group Inc (UNH) Stock Review

**0) Introduction:**

UnitedHealth Group Inc (UNH) is a diversified healthcare company offering a range of health benefits programs and related services.  This report analyzes UNH's recent performance against the S&P 500 (VOO), incorporating financial data, key metrics, and technical indicators.

**1) Performance Comparison:**

* **UNH Cumulative Return:** 42.30%
* **VOO (S&P 500) Cumulative Return:** 72.42%
* **Return Difference:** -30.1%
* **Relative Divergence:** 13.7% (This indicates UNH's underperformance relative to VOO is in the lower 14th percentile of historical divergences.)


The provided Alpha and Beta analysis shows UNH's performance relative to the market (Beta) and its excess return (Alpha) over different periods. While UNH demonstrates positive Alpha in several periods,  indicating outperformance, the overall cumulative return lags significantly behind the S&P 500. The market capitalization (Cap(B)) has steadily increased over the years.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 67.0% | 55.4% | 35.0% | 0.1 | 193.3 |
| 2016-2018  | 59.0% | 63.7% | 38.0% | 0.2 | 221.3 |
| 2017-2019  | 45.0% | 63.7% | 11.0% | 0.4 | 265.6 |
| 2018-2020  | -17.0% | 63.7% | -47.0% | 0.6 | 322.1 |
| 2019-2021  | 39.0% | 61.0% | -22.0% | 0.7 | 467.7 |
| 2020-2022  | 32.0% | 66.9% | 24.0% | 0.7 | 500.1 |
| 2021-2023  | 39.0% | 67.8% | 18.0% | 0.4 | 504.1 |
| 2022-2024  | -27.0% | 69.0% | -47.0% | 0.3 | 491.9 |
| 2023-2025  | -44.0% | 75.1% | -55.0% | 0.2 | 415.4 |


**2) Recent Price Movement:**

* **Closing Price:** $425.33
* **Previous Close:** $454.11
* **Change:** -$6.34 (Significant daily decline)
* **5-Day Moving Average:** $527.03
* **20-Day Moving Average:** $535.04
* **60-Day Moving Average:** $514.84

The price is significantly below all three moving averages, suggesting a downtrend. The large daily decline warrants further investigation into potential underlying news or market factors.


**3) Technical Indicators:**

* **Market Risk Indicator (MRI):** 0.4082 (Medium Risk)
* **RSI:** 32.76 (Suggests oversold conditions, but should be interpreted cautiously in conjunction with other indicators)
* **PPO:** -2.20 (Negative value indicating bearish momentum)
* **Recent (20-day) Relative Divergence Change:** -44.8% (Strong indication of short-term downtrend)
* **Expected Return (Long-term, vs. S&P 500):** 77.7%  This indicates a high potential for outperformance over the long term, despite the current underperformance.  The large negative daily change (-$6.34) suggests a possible short-term correction or market reaction to some news that needs to be investigated further.

**4) Recent Earnings Analysis:**

| Date       | EPS   | Revenue       |
|------------|-------|----------------|
| 2024-11-04 | 6.56  | $100.82 B     |
| 2024-08-09 | 4.58  | $98.86 B      |
| 2024-05-09 | -1.53 | $99.80 B      |
| 2023-11-06 | 6.31  | $92.36 B      |
| 2024-11-04 | 6.31  | $92.36 B      | *(Duplicate entry, likely an error)*

Revenue remains consistently high, though EPS shows significant fluctuation.  The negative EPS in Q2 2024 warrants further investigation into the contributing factors. The duplicate entry needs clarification.

**5) Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue    | Profit Margin |
|---------|------------|---------------|
| 2024-12-31 | $100.81B  | 21.14%        |
| 2024-09-30 | $100.82B  | 22.84%        |
| 2024-06-30 | $98.86B   | 22.31%        |
| 2024-03-31 | $99.80B   | 23.05%        |
| 2023-12-31 | $94.43B   | 23.30%        |

Revenue is generally stable and high. Profit margins are consistently strong, although they show a slight downward trend in recent quarters.

**Capital and Profitability:**

| Quarter | Equity     | ROE    |
|---------|------------|--------|
| 2024-12-31 | $92.66B   | 5.98%  |
| 2024-09-30 | $94.53B   | 6.41%  |
| 2024-06-30 | $89.36B   | 4.72%  |
| 2024-03-31 | $86.69B   | -1.63% |
| 2023-12-31 | $88.76B   | 6.15%  |

Equity shows some fluctuation, and ROE also varies, with a notable negative value in Q1 2024 which needs further investigation.


**6) Overall Analysis:**

UNH shows strong revenue and generally high profit margins, indicating a healthy financial position. However, the recent price decline, negative PPO, and significant underperformance relative to the S&P 500 raise concerns.  The negative EPS and ROE in Q1 2024 require further analysis to understand the contributing factors. The high expected long-term return suggests potential for future growth, but the current market conditions and recent price action indicate caution.  Further investigation into the reasons for the Q2 2024 negative EPS and the large daily price drop is crucial before making any investment decisions.  Investors should carefully consider the risks and potential rewards before investing in UNH.  Additional fundamental and technical analysis, as well as news analysis, is recommended.
